

Characteristics	ImmunoMSI, N = 73 [†]	Nipicol, N = 47 [†]
Age	58 (15)	54 (13)
Unknown	2	0
Sex		
Female	27 / 71 (38%)	19 / 47 (40%)
Male	44 / 71 (62%)	28 / 47 (60%)
Unknown	2	0
ECOG performance score		
≥1	36 / 71 (51%)	29 / 47 (62%)
0	35 / 71 (49%)	18 / 47 (38%)
Unknown	2	0
Primary tumor location		
Left colon	23 / 73 (32%)	18 / 47 (38%)
Right colon	47 / 73 (64%)	28 / 47 (60%)
Unknown	3 / 73 (4.1%)	1 / 47 (2.1%)
BRAF		

Characteristics	ImmunoMSI, N = 73 ¹	Nipicol, N = 47 ¹
Mutated	22 / 73 (30%)	7 / 47 (15%)
Unknown	2 / 73 (2.7%)	3 / 47 (6.4%)
Wild type	49 / 73 (67%)	37 / 47 (79%)
KRAS		
Mutated	21 / 71 (30%)	23 / 47 (49%)
Wild type	50 / 71 (70%)	24 / 47 (51%)
Unknown	2	0
NRAS		
Mutated	1 / 73 (1.4%)	1 / 47 (2.1%)
Unknown	2 / 73 (2.7%)	4 / 47 (8.5%)
Wild type	70 / 73 (96%)	42 / 47 (89%)
Origin of MMR deficiency		
Known germline mutation	20 / 73 (27%)	27 / 47 (57%)
Sporadic	10 / 73 (14%)	12 / 47 (26%)
Unknow	43 / 73 (59%)	8 / 47 (17%)

Characteristics	ImmunoMSI, N = 73 [†]	Nipicol, N = 47 [†]
Surgery of the primary tumor	44 / 71 (62%)	43 / 44 (98%)
Unknown	2	3
Number of metastatic sites		
1	27 / 71 (38%)	14 / 47 (30%)
2	25 / 71 (35%)	18 / 47 (38%)
3	13 / 71 (18%)	10 / 47 (21%)
4	6 / 71 (8.5%)	3 / 47 (6.4%)
5	0 / 71 (0%)	2 / 47 (4.3%)
Unknown	2	0
Number of prior lines		
0	9 / 73 (12%)	0 / 47 (0%)
1	20 / 73 (27%)	8 / 47 (17%)
2	32 / 73 (44%)	22 / 47 (47%)
3	8 / 73 (11%)	12 / 47 (26%)
4	1 / 73 (1.4%)	3 / 47 (6.4%)

Characteristics	ImmunoMSI, N = 73 ¹	Nipicol, N = 47 ¹
5	1 / 73 (1.4%)	2 / 47 (4.3%)
Unknown	2 / 73 (2.7%)	0 / 47 (0%)
Type of immunotherapy		
Anti-PD1	43 / 71 (61%)	0 / 47 (0%)
Anti-PD1 Anti-CTLA-4	28 / 71 (39%)	47 / 47 (100%)
Unknown	2	0
Status		
MSI	73 / 73 (100%)	44 / 47 (94%)
MSS	0 / 73 (0%)	3 / 47 (6.4%)
¹ Mean (SD); n / N (%)		